Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vrooman LM, Silverman LB. Treatment of childhood acute lymphoblastic leukemia: prognostic factors and clinical advances. Curr Hematol Malig Rep. 2016;11:385–94.

Article  PubMed  Google Scholar 

Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–64.

Article  CAS  PubMed  Google Scholar 

Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101–12.

Article  PubMed  Google Scholar 

Schramm F, zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, et al. Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity. Blood Adv. 2019;3:3688–99.

Article  PubMed  PubMed Central  Google Scholar 

Pieters R, De Groot-Kruseman H, Van Der Velden V, Fiocco M, Van Den Berg H, De Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–2601.

Article  PubMed  Google Scholar 

Maxwell RR, Cole PD. Pharmacogenetic predictors of treatment-related toxicity among children with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12:176–86.

Article  PubMed  Google Scholar 

Robison LL. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Hematol Am Soc Hematol Am Soc Hematol Educ Program 2011;2011:238–42.

Article  Google Scholar 

Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374:833–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. J Clin Oncol. 2018;36:2181–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31:63–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakamoto K, Imamura T, Kihira K, Suzuki K, Ishida H, Morita H, et al. Low incidence of osteonecrosis in childhood acute lymphoblastic leukemia treated with ALL-97 and ALL-02 study of Japan association of childhood leukemia study group. J Clin Oncol. 2018;36:900–7.

Article  CAS  PubMed  Google Scholar 

Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15.

Article  CAS  PubMed  Google Scholar 

Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199–209.

Article  CAS  PubMed  Google Scholar 

Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32:174–84.

Article  CAS  PubMed  Google Scholar 

Hyakuna N, Shimomura Y, Watanabe A, Taga T, Kikuta A, Matsushita T, et al. Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese childhood cancer and leukemia study group. J Pediatr Hematol Oncol. 2014;36:22–29.

Article  CAS  PubMed  Google Scholar 

Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995;17:1–12.

Article  CAS  PubMed  Google Scholar 

Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 2003;101:3809–17.

Article  CAS  PubMed  Google Scholar 

Wellstein A, Giaccone G, Atkins MB, Sausville EA Cytotoxic Drugs. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds). Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e. McGraw-Hill Education: New York, NY, 2017. http://accessmedicine.mhmedical.com/content.aspx?aid=1162546947.

Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, Ballerini A, Matteo C, Gerss J, et al. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica. 2019;104:1812–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kloos RQH, Mathôt R, Pieters R, van der Sluis IM. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. Haematologica. 2021;106:1254–61.

Article  CAS  PubMed  Google Scholar 

Brigitha LJ, Pieters R, van der Sluis IM. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review. Eur J Cancer. 2021;157:238–49.

Article  CAS  PubMed  Google Scholar 

Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29:551–65.

Article  PubMed  Google Scholar 

Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022;36:1749–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281–8.

Article  CAS  PubMed  Google Scholar 

Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162–70.

Article  CAS  PubMed  Google Scholar 

Vary A, Lebellec L, Di Fiore F, Penel N, Cheymol C, Rad E, et al. FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Ther Adv Med Oncol. 2021;13. https://doi.org/10.1177/17588359211029825.

Lund B, Åsberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56:551–9.

Article  PubMed  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

Article  CAS  PubMed  Google Scholar 

Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60.

Article  PubMed  PubMed Central  Google Scholar 

R Core Team. R: A language and environment for statistical computing. 2021. https://www.R-project.org/.

Lancia C, Anninga J, Spitoni C, Sydes MR, Whelan J, Hogendoorn PCW, et al. Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma. BMJ Open. 2019;9:e022980.

Article  PubMed  PubMed Central